TriangleNCT02720510 · OUTCOME
Depth of Response by International Myeloma Working Group (IMWG) Criteria
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Day 22 up to end of study, approximately 3 years
What was measured
Rate of Very Good Partial Response (VGPR), Complete Response (CR) and Stringent Complete Response (sCR)
Analysis population: The study was terminated prematurely and because only 6 patients were enrolled, efficacy data were not evaluated.
Groups in this outcome
Arm 1 - RVD + Pan
Revlimid, Velcade, dexamethasone and Farydak
Arm 2 - RVD
Revlimid, Velcade and Dexamethasone
| Group | Source count |
|---|---|
| Arm 1 - RVD + Pan | 0 |
| Arm 2 - RVD | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- units
- Participants
- description
- Rate of Very Good Partial Response (VGPR), Complete Response (CR) and Stringent Complete Response (sCR)
- groups
- description
- Revlimid, Velcade, dexamethasone and Farydak
- id
- OG000
- title
- Arm 1 - RVD + Pan
- description
- Revlimid, Velcade and Dexamethasone
- id
- OG001
- title
- Arm 2 - RVD
- population Description
- The study was terminated prematurely and because only 6 patients were enrolled, efficacy data were not evaluated.
- reporting Status
- POSTED
- time Frame
- Day 22 up to end of study, approximately 3 years
- title
- Depth of Response by International Myeloma Working Group (IMWG) Criteria
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice